Related Experiment Videos
Extragonadal germ cell tumor: a clinical study
M A Bassetto1, F Pasini, T Franceschi
1Cattedra di Oncologia Medica, Università di Verona, Italy.
Anticancer Research
|November 1, 1995
Summary
Cisplatin-based chemotherapy effectively treats primary extragonadal germ cell tumors, achieving high remission and long-term relapse-free survival rates in most patients. Survival outcomes were similar across different tumor locations and subtypes.
Area of Science:
- Oncology
- Medical research
Background:
- Extragonadal germ cell tumors (EGCTs) are rare neoplasms originating outside the gonads.
- Primary EGCTs require specific treatment strategies due to their unique presentation and potential for metastasis.
Purpose of the Study:
- To evaluate the efficacy of cisplatin-based chemotherapy in patients with primary extragonadal germ cell tumors.
- To assess remission rates, relapse-free survival, and overall survival in this patient cohort.
Main Methods:
- Retrospective analysis of 18 patients diagnosed with primary extragonadal germ cell tumors.
- Treatment involved cisplatin-based chemotherapy for 17 patients.
- Follow-up included assessment of remission status, relapse, and survival data.
Main Results:
- Fifteen out of 18 patients (83%) achieved complete remission.
- 12 patients remain relapse-free after a median follow-up of 82 months.
- Five-year overall survival rate was 65%.
Conclusions:
- Cisplatin-based chemotherapy is an effective treatment for primary extragonadal germ cell tumors.
- Long-term remission and survival are achievable with this therapeutic approach.
- No significant survival differences were observed based on tumor location (mediastinal vs. retroperitoneal) or histology (seminoma vs. non-seminoma).